Announcements Trials
Browse Landscape

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 2Gastrointestinal 1

Conditions

Neoplasms 6Neoplasm Metastasis 2Neoplasm, Residual 1

Interventions

pembrolizumab 34Specimen Handling 26Magnetic Resonance Spectroscopy 26Radiosurgery 25Biopsy 25Gemcitabine 22Nivolumab 21Paclitaxel 18Carboplatin 16Bevacizumab 15Trastuzumab 14Everolimus 12Radiotherapy 11Irinotecan 11trastuzumab deruxtecan 10atezolizumab 10Erlotinib Hydrochloride 10Docetaxel 10Cetuximab 10Capecitabine 10Albumin-Bound Paclitaxel 10130-nm albumin-bound paclitaxel 10Sorafenib 9Ipilimumab 9Cisplatin 9Taxes 8Standard of Care 8Oxaliplatin 8Drug Therapy 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Hematologic Tests × Tumor-Agnostic × Clear all
NCT03409016 2025-09-05

Biomarkers of Immune-Related Toxicity

University of Colorado, Denver

Active not recruiting
69 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03868046 2025-04-01

AUTENTIC

Hospital Universitario Araba

Completed
242 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡